gastric cancer
Conditions
Interventions
Intervention Group:Carrelizumab combined with Sox regimen
Sponsors
The First Affiliated Hospital of USTC WEST district
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18-75 years old, male or female; 2.ECOG score is less than or equal to 1; 3. Patients with pathologically and/or cytologically confirmed gastric cancer Gastric adenocarcinoma or gastric esophageal junction adenocarcinoma 4. Normal function of major organs; 5. Cardiac function was good before enrollment, no myocardial infarction occurred within half a year, hypertension and other coronary heart diseases were within the control range at present; 6. No other uncontrollable benign diseases such as lung, kidney and liver infection before enrollment; 7. Not participating in other clinical studies before and during treatment; 8. Women of childbearing age must have used a reliable contraceptive method or have performed a pregnancy test (serum or urine) within 7 days prior to enrollment with negative results and be willing to use an appropriate method of contraception during the trial period and 8 weeks after the last administration of the trial drug; 9. Subjects voluntarily joined the study, signed informed consent and cooperated with follow-up.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; Female patients of childbearing age and those who wanted to have children during the study; 2. Patients with POSITIVE HER-2 test and BRAF test; 3. Patients with contraindications for surgical treatment and chemotherapy or physical condition and organ function are not allowed to undergo large abdominal surgery; 4. Patients with hypertension (systolic blood pressure >140 mmHg, diastolic blood pressure >90 mmHg) suffering from grade I or above myocardial ischemia or myocardial infarction, arrhythmia and Grade II cardiac insufficiency; 5. Abnormal coagulation function (INR >1.5 or prothrombin time (PT) > ULN+4 seconds or APTT >1.5 ULN), with bleeding tendency or receiving thrombolytic or anticoagulant therapy; 6. Patients with positive urine protein (urine protein test 2+ or above, or 24-hour urine protein quantification > 1.0g); 7. Those who had received other drug therapy before enrollment or could not be guaranteed to follow the study requirements after enrollment; He had previously undergone partial gastrectomy; 8. Drug allergy to this program.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The PCR rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;disease-free survival;R0 removal rate; | — |
Countries
China
Contacts
Public ContactZhongliang Ning
The First Affiliated Hospital of USTC WEST district
Outcome results
None listed